A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer

A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-010-1257-5 ◽

2010 ◽

Vol 66 (6) ◽

pp. 1051-1057 ◽

Cited By ~ 41

Author(s):

Andrew H. Ko ◽

Alan P. Venook ◽

Emily K. Bergsland ◽

R. Kate Kelley ◽

W. Michael Korn ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

A multinational phase II study of PEP02 (liposome irinotecan) for patients with gemcitabine-refractory metastatic pancreatic cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.4069 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 4069-4069 ◽

Cited By ~ 2

Author(s):

A. H. Ko ◽

M. A. Tempero ◽

Y. Shan ◽

W. Su ◽

Y. Lin ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Faculty Opinions recommendation of A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718415927.793495708 ◽

2014 ◽

Author(s):

Alexandru Grigorescu

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Pancreatic Cancer ◽

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

BMC Cancer ◽

10.1186/s12885-015-1656-4 ◽

2015 ◽

Vol 15 (1) ◽

Cited By ~ 4

Author(s):

Jean-Baptiste Bachet ◽

◽

Benoist Chibaudel ◽

Franck Bonnetain ◽

Pierre Validire ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii

Randomized Phase II Study of PARP Inhibitor Veliparib with Modified FOLFIRI versus FOLFIRI as Second Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-1789 ◽

2021 ◽

pp. clincanres.1789.2021

Author(s):

E. Gabriela Chiorean ◽

Katherine A Guthrie ◽

Philip A Philip ◽

Elizabeth M. Swisher ◽

Florencia Jalikis ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Parp Inhibitor ◽

Line Treatment ◽

Second Line ◽

Randomized Phase Ii

A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-1025 ◽

2020 ◽

Vol 26 (19) ◽

pp. 5129-5139 ◽

Cited By ~ 1

Author(s):

Annie A. Wu ◽

Katherine M. Bever ◽

Won Jin Ho ◽

Elana J. Fertig ◽

Nan Niu ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Maintenance Treatment ◽

Pancreatic Tumor ◽

Tumor Vaccine ◽

Phase Ii Study ◽

Gm Csf

Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)

Annals of Oncology ◽

10.1093/annonc/mdw371.84 ◽

2016 ◽

Vol 27 ◽

pp. vi233 ◽

Cited By ~ 2

Author(s):

S. Bozzarelli ◽

L. Rimassa ◽

L. Giordano ◽

S. Sala ◽

M.C. Tronconi ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Open Label ◽

Open Label Phase

First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study

Bulletin du Cancer ◽

10.1684/bdc.2009.0871 ◽

2009 ◽

Vol 96 (5) ◽

pp. e18-e22 ◽

Cited By ~ 8

Author(s):

P. Afchain ◽

B. Chibaudel ◽

G. Lledo ◽

F. Selle ◽

L. Bengrine-Lefevre ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

Randomized Phase Ii

An Eastern Cooperative Oncology Group Phase II Study of Single Agent DHAD, VP-16, Aclacinomycin, or Spirogermanium in Metastatic Pancreatic Cancer

American Journal of Clinical Oncology ◽

10.1097/00000421-199404000-00016 ◽

1994 ◽

Vol 17 (2) ◽

pp. 166-169 ◽

Cited By ~ 15

Author(s):

R. F. Asbury ◽

A. Cnaan ◽

L. Johnson ◽

J. Harris ◽

S. D. Zaentz ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Eastern Cooperative Oncology Group ◽

Oncology Group

Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients

Oncology Letters ◽

10.3892/ol.2012.637 ◽

2012 ◽

Vol 3 (6) ◽

pp. 1314-1318 ◽

Cited By ~ 5

Author(s):

HYUN JUNG KIM ◽

JINA YUN ◽

HAN JO KIM ◽

KYOUNG HA KIM ◽

SE HYUNG KIM ◽

...

Keyword(s):

Pancreatic Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Chemotherapy ◽

Gemcitabine Refractory ◽

Line Chemotherapy